デフォルト表紙
市場調査レポート
商品コード
1387451

強直性脊椎炎治療市場レポート:2030年までの動向、予測、競合分析

Ankylosing Spondylitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.87円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

強直性脊椎炎治療市場レポート:2030年までの動向、予測、競合分析
出版日: 2023年11月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

強直性脊椎炎治療の動向と予測

世界の強直性脊椎炎治療市場は、2024年から2030年までのCAGRが6.5%で、2030年までに推定84億米ドルに達すると予測されます。この市場の主な促進要因は、強直性脊椎炎の罹患率の上昇、疾患に対する認識と診断の高まり、強直性脊椎炎治療の進歩です。世界の強直性脊椎炎治療市場の将来は、病院薬局、小売薬局、オンライン薬局の各市場における機会によって有望視されています。

強直性脊椎炎治療市場の洞察

Lucintelの予測では、強直性脊椎炎の成長により、予測期間中はNSAIDsが引き続き大きなセグメントとなります。

同市場では、小売薬局の数が増加しており、患者にとって利用しやすいことから、小売薬局が引き続き最大セグメントとなります。

北米は、高齢者人口の増加と政府の支援策により、予測期間中最大の地域であり続けると思われます。

本レポートでは、以下の11の主要な質問に回答しています:

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か?
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は?
  • Q.3.今後成長が加速すると思われる地域とその理由は?
  • Q.4.市場力学に影響を与える主な要因は何か?市場における主な課題とビジネスリスクは?
  • Q.5.この市場におけるビジネスリスクと競合の脅威は?
  • Q.6.この市場における新たな動向とその理由は?
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか?
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は?
  • Q.9.この市場における主要企業は?主要企業は事業成長のためにどのような戦略的取り組みを進めているのか?
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか?
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか?

目次

第1章 エグゼクティブサマリー

第2章 世界の強直性脊椎炎治療市場:市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向(2018~2023年)と予測(2024~2030年)
  • 世界の強直性脊椎炎治療市場の動向(2018~2023年)と予測(2024~2030年)
  • 薬剤クラス別の世界の強直性脊椎炎治療市場
    • NSAIDs
    • TNF阻害剤
    • その他
  • 販売チャネル別の世界の強直性脊椎炎治療市場
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の強直性脊椎炎治療市場
  • 北米の強直性脊椎炎治療市場
  • 欧州の強直性脊椎炎治療市場
  • アジア太平洋の強直性脊椎炎治療市場
  • その他地域の強直性脊椎炎治療市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
    • 薬剤クラス別の世界の強直性脊椎炎治療市場の成長機会
    • 流通チャネル別の世界の強直性脊椎炎治療市場の成長機会
    • 地域別の世界の強直性脊椎炎治療市場の成長機会
  • 世界の強直性脊椎炎治療市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の強直性脊椎炎治療市場の能力拡大
    • 世界の強直性脊椎炎治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie
目次

Ankylosing Spondylitis Treatment Trends and Forecast

The future of the global ankylosing spondylitis treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global ankylosing spondylitis treatment market is expected to reach an estimated $8.4 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising occurence of ankylosing spondylitis, growing awareness and diagnosis of condition, and advancement in ankylosing spondylitis therapy.

A more than 150-page report is developed to help in your business decisions.

Ankylosing Spondylitis Treatment by Segment

The study includes a forecast for the global ankylosing spondylitis treatment by drug class, distribution channel, and region.

Ankylosing Spondylitis Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • NSAIDs
  • TNF Inhibitors
  • Others

Ankylosing Spondylitis Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Ankylosing Spondylitis Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Ankylosing Spondylitis Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ankylosing spondylitis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ankylosing spondylitis treatment companies profiled in this report include-

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie

Ankylosing Spondylitis Treatment Market Insights

Lucintel forecasts that NSAIDs will remain the larger segment over the forecast period due to growth of ankylosing spondylitis.

Within this market, retail pharmacy will remain the largest segment due to growing number of retail pharmacies and it is easy to reach for patients.

North America will remain the largest region over the forecast period due to growth of geriatric population and supportive government initiatives.

Features of the Global Ankylosing Spondylitis Treatment Market

Market Size Estimates: Ankylosing spondylitis treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Ankylosing spondylitis treatment market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Ankylosing spondylitis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, distribution channels, and regions for the ankylosing spondylitis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ankylosing spondylitis treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the ankylosing spondylitis treatment market size?

Answer: The global ankylosing spondylitis treatment market is expected to reach an estimated $8.4 billion by 2030.

Q2. What is the growth forecast for ankylosing spondylitis treatment market?

Answer: The global ankylosing spondylitis treatment market is expected to grow with a CAGR of 6.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the ankylosing spondylitis treatment market?

Answer: The major drivers for this market are rising occurence of ankylosing spondylitis, growing awareness and diagnosis of condition, and advancement in ankylosing spondylitis therapy.

Q4. What are the major segments for ankylosing spondylitis treatment market?

Answer: The future of the ankylosing spondylitis treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key ankylosing spondylitis treatment market companies?

Answer: Some of the key ankylosing spondylitis treatment companies are as follows:

  • Novartis
  • Amgen
  • Boehringer Ingelheim International
  • UCB Biopharma
  • AbbVie

Q6. Which ankylosing spondylitis treatment market segment will be the largest in future?

Answer: Lucintel forecasts that NSAIDs will remain the larger segment over the forecast period due to growth of ankylosing spondylitis.

Q7. In ankylosing spondylitis treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growth of geriatric population and supportive government initiatives.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ankylosing spondylitis treatment market by drug class (NSAIDs, TNF inhibitors, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ankylosing Spondylitis Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Ankylosing Spondylitis Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Ankylosing Spondylitis Treatment Market by Drug Class
    • 3.3.1: NSAIDs
    • 3.3.2: TNF Inhibitors
    • 3.3.3: Others
  • 3.4: Global Ankylosing Spondylitis Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Online Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Ankylosing Spondylitis Treatment Market by Region
  • 4.2: North American Ankylosing Spondylitis Treatment Market
    • 4.2.2: North American Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.3: European Ankylosing Spondylitis Treatment Market
    • 4.3.1: European Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.3.2: European Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.4: APAC Ankylosing Spondylitis Treatment Market
    • 4.4.1: APAC Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.4.2: APAC Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
  • 4.5: ROW Ankylosing Spondylitis Treatment Market
    • 4.5.1: ROW Ankylosing Spondylitis Treatment Market by Drug Class: NSAIDs, TNF Inhibitors, and Others
    • 4.5.2: ROW Ankylosing Spondylitis Treatment Market by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Ankylosing Spondylitis Treatment Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Ankylosing Spondylitis Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Ankylosing Spondylitis Treatment Market by Region
  • 6.2: Emerging Trends in the Global Ankylosing Spondylitis Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Ankylosing Spondylitis Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ankylosing Spondylitis Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Amgen
  • 7.3: Boehringer Ingelheim International
  • 7.4: UCB Biopharma
  • 7.5: AbbVie